Stock comparison
Grifols
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GRFS
Grifols
Market cap
$6.48B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GRFS | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 55C | 61C | UTHR |
| Benjamin Graham | 50C | 66B | UTHR |
| Philip Fisher | 46D | 66B | UTHR |
| Peter Lynch | 40D | 52C | UTHR |
| Joel Greenblatt | 22F | 36D | UTHR |
| Charlie Munger | 40D | 54C | UTHR |
| Terry Smith | 43D | 54C | UTHR |
Side-by-side metrics
| Metric | GRFS | UTHR |
|---|---|---|
| Market cap | $6.48B | $24.13B |
| P/E (TTM) | 14.9x | 19.2x |
| EV/EBIT | 12.8x | 15.2x |
| ROIC (TTM) | 5.49% | 18.81% |
| Gross margin | 37.68% | 86.58% |
| Net margin | 5.58% | 40.61% |
| Revenue CAGR 5y | 10.02% | 17.22% |
| EPS CAGR 5y | 20.54% | 29.84% |
| Debt / Equity | 1.8x | - |
| Dividend yield | 1.65% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GRFS leads on
- Dividend yield1.65%vs 0.0%+100%
- P/E (TTM)14.9xvs 19.2x+22%
- EV/EBIT12.8xvs 15.2x+16%
UTHR leads on
- Debt / Equity-vs 1.8x+100%
- Net margin40.61%vs 5.58%+86%
- Market cap$24.13Bvs $6.48B+73%
- ROIC (TTM)18.81%vs 5.49%+71%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.